Attached files
| file | filename |
|---|---|
| 8-K - JOHNSON & JOHNSON | eightkthirdquarter2009.htm |
| EX-99.15 OTH FIN ST - JOHNSON & JOHNSON | exhibit99153q2009.htm |
Exhibit 99.2O
|
Johnson
& Johnson and Subsidiaries
|
|||||||||||
|
Condensed
Consolidated Statement of Earnings
|
|||||||||||
|
|
|||||||||||
|
|
|
|
|
|
|||||||
|
(Unaudited;
in Millions Except Per Share Figures)
|
THIRD
QUARTER
|
||||||||||
|
2009
|
2008
|
Percent
|
|||||||||
|
Percent
|
Percent
|
Increase
|
|||||||||
|
Amount
|
to
Sales
|
|
Amount
|
to
Sales
|
(Decrease)
|
||||||
|
Sales
to customers
|
$ 15,081
|
100.0
|
$ 15,921
|
100.0
|
(5.3)
|
||||||
|
Cost
of products sold
|
4,434
|
29.4
|
4,774
|
30.0
|
(7.1)
|
||||||
|
Selling,
marketing and administrative expenses
|
4,767
|
31.6
|
5,195
|
32.6
|
(8.2)
|
||||||
|
Research
expense
|
1,617
|
10.7
|
1,861
|
11.7
|
(13.1)
|
||||||
|
Interest
(income)expense, net
|
114
|
0.7
|
25
|
0.2
|
|||||||
|
Other
(income)expense, net
|
(96)
|
(0.6)
|
(224)
|
(1.4)
|
|||||||
|
Earnings
before provision for taxes on income
|
4,245
|
28.2
|
4,290
|
26.9
|
(1.0)
|
||||||
|
Provision
for taxes on income
|
900
|
6.0
|
980
|
6.1
|
(8.2)
|
||||||
|
Net
earnings
|
$ 3,345
|
22.2
|
$ 3,310
|
20.8
|
1.1
|
||||||
|
Net
earnings per share (Diluted)
|
$ 1.20
|
$ 1.17
|
2.6
|
||||||||
|
Average
shares outstanding (Diluted)
|
2,793.0
|
2,831.3
|
|||||||||
|
Effective
tax rate
|
21.2
|
%
|
22.8
|
%
|
|
||||||
|
Johnson
& Johnson and Subsidiaries
|
|||||||||||
|
Condensed
Consolidated Statement of Earnings
|
|||||||||||
|
|
|
|
|
|
|||||||
|
(Unaudited;
in Millions Except Per Share Figures)
|
NINE
MONTHS
|
||||||||||
|
2009
|
2008
|
Percent
|
|||||||||
|
Percent
|
Percent
|
Increase
|
|||||||||
|
Amount
|
to
Sales
|
Amount
|
to
Sales
|
(Decrease)
|
|||||||
|
Sales
to customers
|
$ 45,346
|
100.0
|
$ 48,565
|
100.0
|
(6.6)
|
||||||
|
Cost
of products sold
|
13,135
|
29.0
|
14,139
|
29.1
|
(7.1)
|
||||||
|
Selling,
marketing and administrative expenses
|
14,172
|
31.3
|
15,825
|
32.6
|
(10.4)
|
||||||
|
Research
expense
|
4,773
|
10.5
|
5,469
|
11.3
|
(12.7)
|
||||||
|
In-process
research & development
|
-
|
-
|
40
|
0.1
|
|||||||
|
Interest
(income)expense, net
|
280
|
0.6
|
57
|
0.1
|
|||||||
|
Other
(income)expense, net
|
(165)
|
(0.4)
|
(377)
|
(0.8)
|
|
||||||
|
Earnings
before provision for taxes on income
|
13,151
|
29.0
|
13,412
|
27.6
|
(1.9)
|
||||||
|
Provision
for taxes on income
|
3,091
|
6.8
|
3,177
|
6.5
|
(2.7)
|
||||||
|
Net
earnings
|
$ 10,060
|
22.2
|
$ 10,235
|
21.1
|
(1.7)
|
||||||
|
|
|||||||||||
|
Net
earnings per share (Diluted)
|
$ 3.61
|
$ 3.60
|
0.3
|
||||||||
|
Average
shares outstanding (Diluted)
|
2,787.9
|
2,847.8
|
|||||||||
|
Effective
tax rate
|
23.5
|
%
|
23.7
|
%
|
|
||||||
|
Adjusted
earnings before provision for taxes and net earnings
(A)
|
|||||||||||
| Earnings before provision for taxes |
|
|
|
|
|
||||||
| on income | $ 13,151 |
29.0
|
$ 13,452
|
(1) |
27.7
|
(2.2)
|
|||||
|
Net
earnings
|
$ 10,060
|
22.2
|
$ 10,275
|
(1)
|
21.2
|
(2.1)
|
|||||
|
Net
earnings per share (Diluted)
|
$ 3.61
|
$ 3.61
|
(1)
|
0.0
|
|||||||
|
Effective
tax rate
|
23.5
|
% |
23.6
|
% | |||||||
|
(1)
The difference between as reported earnings and as adjusted earnings
before provision for taxes on income and net earnings and net earnings per
share (diluted) is IPR&D of $40 million with no tax benefit and $0.01
per share, respectively.
|
|||||||||||
|
|
|||||||||||
(A)
NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on
income," "adjusted net earnings," "adjusted net earnings per share (diluted),"
and "adjusted effective tax rate" are non-GAAP financial measures and should not
be considered replacements for GAAP results. The Company provides earnings
before provision for taxes on income, net earnings, net earnings per share
(diluted), and effective tax rate on an adjusted basis because management
believes that these measures provide useful information to investors. Among
other things, they may assist investors in evaluating the Company's results of
operations period over period. In various periods, these measures may exclude
such items as business development activities (including IPR&D at
acquisition or upon attainment of milestones and any extraordinary expenses),
strategic developments (including restructuring and product line changes),
significant litigation, and changes in applicable laws and regulations
(including significant accounting or tax matters). Special items may be highly
variable, difficult to predict, and of a size that sometimes has substantial
impact on the Company's reported results of operations for a period. Management
uses these measures internally for planning, forecasting and evaluating the
performances of the Company's businesses, including allocating resources and
evaluating results relative to employee performance compensation
targets. Unlike earnings before provision for taxes on income, net
earnings, net earnings per share (diluted), and effective tax rate prepared in
accordance with GAAP, adjusted earnings before provision for taxes on income,
adjusted net earnings, adjusted net earnings per share (diluted), and adjusted
effective tax rate may not be comparable with the calculation of similar
measures for other companies. These non-GAAP financial measures are presented
solely to permit investors to more fully understand how management assesses the
performance of the Company. The limitations of using these non-GAAP financial
measures as performance measures are that they provide a view of the Company's
results of operations without including all events during a period, such as the
effects of an acquisition, merger-related or other restructuring charges, or
amortization of purchased intangibles, and do not provide a comparable view of
the Company's performance to other companies in the health care industry.
Investors should consider non-GAAP financial measures in addition to, and not as
replacements for, or superior to, measures of financial performance prepared in
accordance with GAAP.
|
Johnson
& Johnson and Subsidiaries
|
||||||||||||||||||||
|
Supplementary
Sales Data
|
||||||||||||||||||||
|
(Unaudited;
Dollars in Millions)
|
THIRD
QUARTER
|
|||||||||||||||||||
|
Percent
Change
|
||||||||||||||||||||
|
2009
|
2008
|
Total
|
Operations
|
Currency
|
||||||||||||||||
|
Sales
to customers by
|
||||||||||||||||||||
|
segment
of business
|
||||||||||||||||||||
|
Consumer
|
||||||||||||||||||||
|
U.S.
|
$ | 1,691 | 1,769 | (4.4 | ) % | (4.4 | ) | - | ||||||||||||
|
International
|
2,298 | 2,330 | (1.4 | ) | 5.2 | (6.6 | ) | |||||||||||||
| 3,989 | 4,099 | (2.7 | ) | 1.1 | (3.8 | ) | ||||||||||||||
|
Pharmaceutical
|
||||||||||||||||||||
|
U.S.
|
2,857 | 3,538 | (19.2 | ) | (19.2 | ) | - | |||||||||||||
|
International
|
2,392 | 2,575 | (7.1 | ) | (1.9 | ) | (5.2 | ) | ||||||||||||
| 5,249 | 6,113 | (14.1 | ) | (11.9 | ) | (2.2 | ) | |||||||||||||
|
Med
Devices & Diagnostics
|
||||||||||||||||||||
|
U.S.
|
2,766 | 2,648 | 4.5 | 4.5 | - | |||||||||||||||
|
International
|
3,077 | 3,061 | 0.5 | 3.8 | (3.3 | ) | ||||||||||||||
|
|
5,843 | 5,709 | 2.3 | 4.1 | (1.8 | ) | ||||||||||||||
|
U.S.
|
7,314 | 7,955 | (8.1 | ) | (8.1 | ) | - | |||||||||||||
|
International
|
7,767 | 7,966 | (2.5 | ) | 2.4 | (4.9 | ) | |||||||||||||
|
Worldwide
|
$ | 15,081 | 15,921 | (5.3 | ) % | (2.8 | ) | (2.5 | ) | |||||||||||
|
Johnson
& Johnson and Subsidiaries
|
||||||||||||||||||||
|
Supplementary
Sales Data
|
||||||||||||||||||||
|
(Unaudited;
Dollars in Millions)
|
NINE MONTHS | |||||||||||||||||||
|
Percent
Change
|
||||||||||||||||||||
|
2009
|
2008
|
Total
|
Operations
|
Currency
|
||||||||||||||||
|
Sales
to customers by
|
||||||||||||||||||||
|
segment
of business
|
||||||||||||||||||||
|
Consumer
|
||||||||||||||||||||
|
U.S.
|
$ | 5,125 | 5,282 | (3.0 | ) % | (3.0 | ) | - | ||||||||||||
|
International
|
6,429 | 6,917 | (7.1 | ) | 4.1 | (11.2 | ) | |||||||||||||
| 11,554 | 12,199 | (5.3 | ) | 1.0 | (6.3 | ) | ||||||||||||||
|
Pharmaceutical
|
||||||||||||||||||||
|
U.S.
|
9,703 | 11,401 | (14.9 | ) | (14.9 | ) | - | |||||||||||||
|
International
|
6,824 | 7,481 | (8.8 | ) | 1.4 | (10.2 | ) | |||||||||||||
| 16,527 | 18,882 | (12.5 | ) | (8.5 | ) | (4.0 | ) | |||||||||||||
|
Med
Devices & Diagnostics
|
||||||||||||||||||||
|
U.S.
|
8,194 | 7,959 | 3.0 | 3.0 | - | |||||||||||||||
|
International
|
9,071 | 9,525 | (4.8 | ) | 3.7 | (8.5 | ) | |||||||||||||
|
|
17,265 | 17,484 | (1.3 | ) | 3.3 | (4.6 | ) | |||||||||||||
|
U.S.
|
23,022 | 24,642 | (6.6 | ) | (6.6 | ) | - | |||||||||||||
|
International
|
22,324 | 23,923 | (6.7 | ) | 3.1 | (9.8 | ) | |||||||||||||
|
Worldwide
|
$ | 45,346 | 48,565 | (6.6 | ) % | (1.8 | ) | (4.8 | ) | |||||||||||
|
Johnson
& Johnson and Subsidiaries
|
||||||||||||||||||||
|
Supplementary
Sales Data
|
||||||||||||||||||||
|
(Unaudited;
Dollars in Millions)
|
THIRD
QUARTER
|
|||||||||||||||||||
|
Percent
Change
|
||||||||||||||||||||
|
2009
|
2008
|
Total
|
Operations
|
Currency
|
||||||||||||||||
|
Sales
to customers by
|
||||||||||||||||||||
|
geographic
area
|
||||||||||||||||||||
|
U.S.
|
$ | 7,314 | 7,955 | (8.1 | ) % | (8.1 | ) | - | ||||||||||||
|
Europe
|
3,879 | 4,076 | (4.8 | ) | 2.1 | (6.9 | ) | |||||||||||||
|
Western
Hemisphere excluding U.S.
|
1,338 | 1,461 | (8.4 | ) | 1.5 | (9.9 | ) | |||||||||||||
|
Asia-Pacific,
Africa
|
2,550 | 2,429 | 5.0 | 3.5 | 1.5 | |||||||||||||||
|
International
|
7,767 | 7,966 | (2.5 | ) | 2.4 | (4.9 | ) | |||||||||||||
|
Worldwide
|
$ | 15,081 | 15,921 | (5.3 | ) % | (2.8 | ) | (2.5 | ) | |||||||||||
|
Johnson
& Johnson and Subsidiaries
|
||||||||||||||||||||
|
Supplementary
Sales Data
|
||||||||||||||||||||
|
(Unaudited;
Dollars in Millions)
|
NINE MONTHS | |||||||||||||||||||
|
Percent
Change
|
||||||||||||||||||||
|
2009
|
2008
|
Total
|
Operations
|
Currency
|
||||||||||||||||
|
Sales
to customers by
|
||||||||||||||||||||
|
geographic
area
|
||||||||||||||||||||
|
U.S.
|
$ | 23,022 | 24,642 | (6.6 | ) % | (6.6 | ) | - | ||||||||||||
|
Europe
|
11,522 | 12,931 | (10.9 | ) | 1.2 | (12.1 | ) | |||||||||||||
|
Western
Hemisphere excluding U.S.
|
3,615 | 3,986 | (9.3 | ) | 5.8 | (15.1 | ) | |||||||||||||
|
Asia-Pacific,
Africa
|
7,187 | 7,006 | 2.6 | 5.1 | (2.5 | ) | ||||||||||||||
|
International
|
22,324 | 23,923 | (6.7 | ) | 3.1 | (9.8 | ) | |||||||||||||
|
Worldwide
|
$ | 45,346 | 48,565 | (6.6 | ) % | (1.8 | ) | (4.8 | ) | |||||||||||
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
THIRD
QUARTER
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
CONSUMER
SEGMENT (2)
|
|||||||||
|
SKIN
CARE
|
|||||||||
|
US
|
370
|
358
|
3.4%
|
3.4%
|
-
|
||||
|
Intl
|
472
|
500
|
(5.6%)
|
(0.1%)
|
(5.5%)
|
||||
|
WW
|
842
|
858
|
(1.9%)
|
1.3%
|
(3.2%)
|
||||
|
BABY
CARE
|
|||||||||
|
US
|
102
|
114
|
(10.5%)
|
(10.5%)
|
-
|
||||
|
Intl
|
442
|
472
|
(6.4%)
|
(0.7%)
|
(5.7%)
|
||||
|
WW
|
544
|
586
|
(7.2%)
|
(2.6%)
|
(4.6%)
|
||||
|
ORAL
CARE
|
|||||||||
|
US
|
187
|
204
|
(8.3%)
|
(8.3%)
|
-
|
||||
|
Intl
|
223
|
230
|
(3.0%)
|
4.8%
|
(7.8%)
|
||||
|
WW
|
410
|
434
|
(5.5%)
|
(1.4%)
|
(4.1%)
|
||||
|
OTC/NUTRITIONALS
|
|||||||||
|
US
|
732
|
778
|
(5.9%)
|
(5.9%)
|
-
|
||||
|
Intl
|
666
|
661
|
0.8%
|
8.0%
|
(7.2%)
|
||||
|
WW
|
1,398
|
1,439
|
(2.8%)
|
0.5%
|
(3.3%)
|
||||
|
WOMEN'S
HEALTH
|
|||||||||
|
US
|
142
|
164
|
(13.4%)
|
(13.4%)
|
-
|
||||
|
Intl
|
360
|
346
|
4.0%
|
11.7%
|
(7.7%)
|
||||
|
WW
|
502
|
510
|
(1.6%)
|
3.6%
|
(5.2%)
|
||||
|
WOUND
CARE / OTHER
|
|||||||||
|
US
|
158
|
151
|
4.6%
|
4.6%
|
-
|
||||
|
Intl
|
135
|
121
|
11.6%
|
18.0%
|
(6.4%)
|
||||
|
WW
|
293
|
272
|
7.7%
|
10.5%
|
(2.8%)
|
||||
|
TOTAL
CONSUMER
|
|||||||||
|
US
|
1,691
|
1,769
|
(4.4%)
|
(4.4%)
|
-
|
||||
|
Intl
|
2,298
|
2,330
|
(1.4%)
|
5.2%
|
(6.6%)
|
||||
|
WW
|
3,989
|
4,099
|
(2.7%)
|
1.1%
|
(3.8%)
|
||||
|
Note:
See footnotes at end of schedule
|
|||||||||
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
NINE
MONTHS
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
CONSUMER
SEGMENT (2)
|
|||||||||
|
SKIN
CARE
|
|||||||||
|
US
|
1,204
|
1,119
|
7.6%
|
7.6%
|
-
|
||||
|
Intl
|
1,313
|
1,418
|
(7.4%)
|
3.0%
|
(10.4%)
|
||||
|
WW
|
2,517
|
2,537
|
(0.8%)
|
5.0%
|
(5.8%)
|
||||
|
BABY
CARE
|
|||||||||
|
US
|
308
|
340
|
(9.4%)
|
(9.4%)
|
-
|
||||
|
Intl
|
1,233
|
1,351
|
(8.7%)
|
0.7%
|
(9.4%)
|
||||
|
WW
|
1,541
|
1,691
|
(8.9%)
|
(1.4%)
|
(7.5%)
|
||||
|
ORAL
CARE
|
|||||||||
|
US
|
549
|
588
|
(6.6%)
|
(6.6%)
|
-
|
||||
|
Intl
|
612
|
640
|
(4.4%)
|
8.3%
|
(12.7%)
|
||||
|
WW
|
1,161
|
1,228
|
(5.5%)
|
1.1%
|
(6.6%)
|
||||
|
OTC/NUTRITIONALS
|
|||||||||
|
US
|
2,137
|
2,299
|
(7.0%)
|
(7.0%)
|
-
|
||||
|
Intl
|
1,919
|
2,139
|
(10.3%)
|
1.8%
|
(12.1%)
|
||||
|
WW
|
4,056
|
4,438
|
(8.6%)
|
(2.8%)
|
(5.8%)
|
||||
|
WOMEN'S
HEALTH
|
|||||||||
|
US
|
443
|
470
|
(5.7%)
|
(5.7%)
|
-
|
||||
|
Intl
|
963
|
1,005
|
(4.2%)
|
7.2%
|
(11.4%)
|
||||
|
WW
|
1,406
|
1,475
|
(4.7%)
|
3.1%
|
(7.8%)
|
||||
|
WOUND
CARE / OTHER
|
|||||||||
|
US
|
484
|
466
|
3.9%
|
3.9%
|
-
|
||||
|
Intl
|
389
|
364
|
6.9%
|
18.8%
|
(11.9%)
|
||||
|
WW
|
873
|
830
|
5.2%
|
10.5%
|
(5.3%)
|
||||
|
TOTAL
CONSUMER
|
|||||||||
|
US
|
5,125
|
5,282
|
(3.0%)
|
(3.0%)
|
-
|
||||
|
Intl
|
6,429
|
6,917
|
(7.1%)
|
4.1%
|
(11.2%)
|
||||
|
WW
|
11,554
|
12,199
|
(5.3%)
|
1.0%
|
(6.3%)
|
||||
|
Note:
See footnotes at end of schedule
|
|||||||||
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
THIRD
QUARTER
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
PHARMACEUTICAL
SEGMENT (2)
|
|||||||||
|
ACIPHEX/PARIET
|
|||||||||
|
US
|
131
|
130
|
0.8%
|
0.8%
|
-
|
||||
|
Intl
|
130
|
152
|
(14.5%)
|
(9.0%)
|
(5.5%)
|
||||
|
WW
|
261
|
282
|
(7.4%)
|
(4.4%)
|
(3.0%)
|
||||
|
|
|
||||||||
|
CONCERTA
|
|||||||||
|
US
|
205
|
190
|
7.9%
|
7.9%
|
-
|
||||
|
Intl
|
79
|
208
|
(62.0%)
|
(59.2%)
|
(2.8%)
|
||||
|
WW
|
284
|
398
|
(28.6%)
|
(27.2%)
|
(1.4%)
|
||||
|
DURAGESIC/FENTANYL
TRANSDERMAL
|
|||||||||
|
US
|
38
|
54
|
(29.6%)
|
(29.6%)
|
-
|
||||
|
Intl
|
168
|
205
|
(18.0%)
|
(15.2%)
|
(2.8%)
|
||||
|
WW
|
206
|
259
|
(20.5%)
|
(18.3%)
|
(2.2%)
|
||||
|
LEVAQUIN/FLOXIN
|
|||||||||
|
US
|
294
|
313
|
(6.1%)
|
(6.1%)
|
-
|
||||
|
Intl
|
17
|
20
|
(15.0%)
|
0.3%
|
(15.3%)
|
||||
|
WW
|
311
|
333
|
(6.6%)
|
(5.7%)
|
(0.9%)
|
||||
|
PROCRIT/EXPREX
|
|||||||||
|
US
|
299
|
334
|
(10.5%)
|
(10.5%)
|
-
|
||||
|
Intl
|
243
|
285
|
(14.7%)
|
(9.6%)
|
(5.1%)
|
||||
|
WW
|
542
|
619
|
(12.4%)
|
(10.0%)
|
(2.4%)
|
||||
|
|
|||||||||
|
RAZADYNE/REMINYL
|
|||||||||
|
US
|
1
|
31
|
(96.8%)
|
(96.8%)
|
-
|
||||
|
Intl
|
96
|
107
|
(10.3%)
|
(3.8%)
|
(6.5%)
|
||||
|
WW
|
97
|
138
|
(29.7%)
|
(24.7%)
|
(5.0%)
|
||||
|
|
|||||||||
|
REMICADE
|
|||||||||
|
US
|
822
|
778
|
5.7%
|
5.7%
|
-
|
||||
|
US
Exports (4)
|
208
|
198
|
5.1%
|
5.1%
|
-
|
||||
|
Intl
|
6
|
2
|
200.0%
|
198.7%
|
1.3%
|
||||
|
WW
|
1,036
|
978
|
5.9%
|
5.9%
|
-
|
||||
Note: See footnotes at end of schedule
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
THIRD
QUARTER
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
PHARMACEUTICAL
SEGMENT (2)
(CONTINUED)
|
|||||||||
|
RISPERDAL/RISPERIDONE
|
|||||||||
|
US
|
35
|
122
|
(71.3%)
|
(71.3%)
|
-
|
||||
|
Intl
|
157
|
198
|
(20.7%)
|
(21.4%)
|
0.7%
|
||||
|
WW
|
192
|
320
|
(40.0%)
|
(40.4%)
|
0.4%
|
||||
|
|
|||||||||
|
RISPERDAL
CONSTA
|
|||||||||
|
US
|
129
|
118
|
9.3%
|
9.3%
|
-
|
||||
|
Intl
|
224
|
220
|
1.8%
|
10.2%
|
(8.4%)
|
||||
|
WW
|
353
|
338
|
4.4%
|
9.9%
|
(5.5%)
|
||||
|
|
|||||||||
|
TOPAMAX
|
|||||||||
|
US
|
72
|
606
|
(88.1%)
|
(88.1%)
|
-
|
||||
|
Intl
|
103
|
122
|
(15.6%)
|
(7.9%)
|
(7.7%)
|
||||
|
WW
|
175
|
728
|
(76.0%)
|
(74.7%)
|
(1.3%)
|
||||
|
|
|||||||||
|
VELCADE
|
|||||||||
|
US
|
-
|
1
|
(100.0%)
|
(100.0%)
|
-
|
||||
|
Intl
|
231
|
189
|
22.2%
|
31.1%
|
(8.9%)
|
||||
|
WW
|
231
|
190
|
21.6%
|
30.5%
|
(8.9%)
|
||||
|
OTHER
|
|||||||||
|
US
|
623
|
663
|
(6.0%)
|
(6.0%)
|
-
|
||||
|
Intl
|
938
|
867
|
8.2%
|
13.6%
|
(5.4%)
|
||||
|
WW
|
1,561
|
1,530
|
2.0%
|
5.1%
|
(3.1%)
|
||||
|
|
|||||||||
|
TOTAL
PHARMACEUTICAL
|
|||||||||
|
US
|
2,857
|
3,538
|
(19.2%)
|
(19.2%)
|
-
|
||||
|
Intl
|
2,392
|
2,575
|
(7.1%)
|
(1.9%)
|
(5.2%)
|
||||
|
WW
|
5,249
|
6,113
|
(14.1%)
|
(11.9%)
|
(2.2%)
|
||||
|
MAJOR
NEW PHARMACEUTICAL PRODUCTS
(5)
|
|||||||||
|
PREZISTA
|
|||||||||
|
US
|
78
|
34
|
129.4%
|
129.4%
|
-
|
||||
|
Intl
|
73
|
45
|
62.2%
|
77.0%
|
(14.8%)
|
||||
|
WW
|
151
|
79
|
91.1%
|
99.5%
|
(8.4%)
|
||||
|
INVEGA
|
|||||||||
|
US
|
61
|
73
|
(16.4%)
|
(16.4%)
|
-
|
||||
|
Intl
|
36
|
16
|
125.0%
|
142.5%
|
(17.5%)
|
||||
|
WW
|
97
|
89
|
9.0%
|
12.3%
|
(3.3%)
|
||||
|
Note:
See footnotes at end of schedule
|
|||||||||
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
NINE
MONTHS
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
PHARMACEUTICAL
SEGMENT (2)
|
|||||||||
|
ACIPHEX/PARIET
|
||||||||
|
US
|
397
|
399
|
(0.5%)
|
(0.5%)
|
-
|
|||
|
Intl
|
387
|
485
|
(20.2%)
|
(9.3%)
|
(10.9%)
|
|||
|
WW
|
784
|
884
|
(11.3%)
|
(5.3%)
|
(6.0%)
|
|||
|
|
|
|||||||
|
CONCERTA
|
||||||||
|
US
|
707
|
622
|
13.7%
|
13.7%
|
-
|
|||
|
Intl
|
238
|
345
|
(31.0%)
|
(20.8%)
|
(10.2%)
|
|||
|
WW
|
945
|
967
|
(2.3%)
|
1.3%
|
(3.6%)
|
|||
|
|
|
|||||||
|
DURAGESIC/FENTANYL
TRANSDERMAL
|
||||||||
|
US
|
163
|
199
|
(18.1%)
|
(18.1%)
|
-
|
|||
|
Intl
|
492
|
565
|
(12.9%)
|
(4.3%)
|
(8.6%)
|
|||
|
WW
|
655
|
764
|
(14.3%)
|
(8.0%)
|
(6.3%)
|
|||
|
LEVAQUIN/FLOXIN
|
||||||||
|
US
|
1,045
|
1,117
|
(6.4%)
|
(6.4%)
|
-
|
|||
|
Intl
|
53
|
63
|
(15.9%)
|
1.4%
|
(17.3%)
|
|||
|
WW
|
1,098
|
1,180
|
(6.9%)
|
(6.0%)
|
(0.9%)
|
|||
|
PROCRIT/EXPREX
|
||||||||
|
US
|
950
|
1,014
|
(6.3%)
|
(6.3%)
|
-
|
|||
|
Intl
|
719
|
886
|
(18.8%)
|
(9.0%)
|
(9.8%)
|
|||
|
WW
|
1,669
|
1,900
|
(12.2%)
|
(7.6%)
|
(4.6%)
|
|||
|
|
||||||||
|
RAZADYNE/REMINYL
|
||||||||
|
US
|
30
|
123
|
(75.6%)
|
(75.6%)
|
-
|
|||
|
Intl
|
275
|
316
|
(13.0%)
|
(1.2%)
|
(11.8%)
|
|||
|
WW
|
305
|
439
|
(30.5%)
|
(22.0%)
|
(8.5%)
|
|||
|
|
||||||||
|
REMICADE
|
||||||||
|
US
|
2,330
|
2,138
|
9.0%
|
9.0%
|
-
|
|||
|
US
Exports (4)
|
821
|
718
|
14.3%
|
14.3%
|
-
|
|||
|
Intl
|
15
|
6
|
150.0%
|
145.8%
|
4.2%
|
|||
|
WW
|
3,166
|
2,862
|
10.6%
|
10.6%
|
-
|
|||
Note: See footnotes at end of schedule
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
NINE
MONTHS
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
PHARMACEUTICAL
SEGMENT (2)
(CONTINUED)
|
|||||||||
|
RISPERDAL/RISPERIDONE
|
||||||||
|
US
|
223
|
1,196
|
(81.4%)
|
(81.4%)
|
-
|
|||
|
Intl
|
483
|
645
|
(25.1%)
|
(21.3%)
|
(3.8%)
|
|||
|
WW
|
706
|
1,841
|
(61.7%)
|
(60.4%)
|
(1.3%)
|
|||
|
|
|
|||||||
|
RISPERDAL
CONSTA
|
||||||||
|
US
|
386
|
339
|
13.9%
|
13.9%
|
-
|
|||
|
Intl
|
640
|
651
|
(1.7%)
|
12.6%
|
(14.3%)
|
|||
|
WW
|
1,026
|
990
|
3.6%
|
13.0%
|
(9.4%)
|
|||
|
|
|
|||||||
|
TOPAMAX
|
||||||||
|
US
|
642
|
1,674
|
(61.6%)
|
(61.6%)
|
-
|
|||
|
Intl
|
317
|
377
|
(15.9%)
|
(3.5%)
|
(12.4%)
|
|||
|
WW
|
959
|
2,051
|
(53.2%)
|
(50.9%)
|
(2.3%)
|
|||
|
|
|
|||||||
|
VELCADE
|
||||||||
|
US
|
-
|
4
|
(100.0%)
|
(100.0%)
|
-
|
|||
|
Intl
|
652
|
575
|
13.4%
|
26.7%
|
(13.3%)
|
|||
|
WW
|
652
|
579
|
12.6%
|
25.8%
|
(13.2%)
|
|||
|
OTHER
|
||||||||
|
US
|
2,009
|
1,858
|
8.1%
|
8.1%
|
-
|
|||
|
Intl
|
2,553
|
2,567
|
(0.5%)
|
9.2%
|
(9.7%)
|
|||
|
WW
|
4,562
|
4,425
|
3.1%
|
8.8%
|
(5.7%)
|
|||
|
|
|
|||||||
|
TOTAL
PHARMACEUTICAL
|
||||||||
|
US
|
9,703
|
11,401
|
(14.9%)
|
(14.9%)
|
-
|
|||
|
Intl
|
6,824
|
7,481
|
(8.8%)
|
1.4%
|
(10.2%)
|
|||
|
WW
|
16,527
|
18,882
|
(12.5%)
|
(8.5%)
|
(4.0%)
|
|||
|
MAJOR
NEW PHARMACEUTICAL PRODUCTS
(5)
|
||||||||
|
PREZISTA
|
||||||||
|
US
|
215
|
109
|
97.2%
|
97.2%
|
-
|
|||
|
Intl
|
198
|
132
|
50.0%
|
70.0%
|
(20.0%)
|
|||
|
WW
|
413
|
241
|
71.4%
|
82.3%
|
(10.9%)
|
|||
|
INVEGA
|
||||||||
|
US
|
194
|
192
|
1.0%
|
1.0%
|
-
|
|||
|
Intl
|
93
|
39
|
138.5%
|
168.1%
|
(29.6%)
|
|||
|
WW
|
287
|
231
|
24.2%
|
29.2%
|
(5.0%)
|
|||
|
Note:
See footnotes at end of schedule
|
||||||||
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
THIRD
QUARTER
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
MEDICAL
DEVICES AND DIAGNOSTICS (2)
(3)
|
|||||||||
|
CORDIS
(6)
|
|||||||||
|
US
|
233
|
259
|
(10.0%)
|
(10.0%)
|
-
|
||||
|
Intl
|
407
|
431
|
(5.6%)
|
(4.6%)
|
(1.0%)
|
||||
|
WW
|
640
|
690
|
(7.2%)
|
(6.6%)
|
(0.6%)
|
||||
|
DEPUY
|
|||||||||
|
US
|
740
|
698
|
6.0%
|
6.0%
|
-
|
||||
|
Intl
|
544
|
533
|
2.1%
|
7.6%
|
(5.5%)
|
||||
|
WW
|
1,284
|
1,231
|
4.3%
|
6.7%
|
(2.4%)
|
||||
|
DIABETES
CARE
|
|||||||||
|
US
|
332
|
349
|
(4.9%)
|
(4.9%)
|
-
|
||||
|
Intl
|
302
|
318
|
(5.0%)
|
(0.4%)
|
(4.6%)
|
||||
|
WW
|
634
|
667
|
(4.9%)
|
(2.7%)
|
(2.2%)
|
||||
|
ETHICON
|
|||||||||
|
US
|
439
|
372
|
18.0%
|
18.0%
|
-
|
||||
|
Intl
|
580
|
585
|
(0.9%)
|
3.8%
|
(4.7%)
|
||||
|
WW
|
1,019
|
957
|
6.5%
|
9.4%
|
(2.9%)
|
||||
|
ETHICON
ENDO-SURGERY
|
|||||||||
|
US
|
499
|
473
|
5.5%
|
5.5%
|
-
|
||||
|
Intl
|
607
|
569
|
6.7%
|
10.9%
|
(4.2%)
|
||||
|
WW
|
1,106
|
1,042
|
6.1%
|
8.4%
|
(2.3%)
|
||||
|
ORTHO-CLINICAL
DIAGNOSTICS
|
|||||||||
|
US
|
285
|
261
|
9.2%
|
9.2%
|
-
|
||||
|
Intl
|
216
|
209
|
3.3%
|
7.0%
|
(3.7%)
|
||||
|
WW
|
501
|
470
|
6.6%
|
8.2%
|
(1.6%)
|
||||
|
VISION
CARE
|
|||||||||
|
US
|
238
|
236
|
0.8%
|
0.8%
|
-
|
||||
|
Intl
|
421
|
416
|
1.2%
|
(0.2%)
|
1.4%
|
||||
|
WW
|
659
|
652
|
1.1%
|
0.2%
|
0.9%
|
||||
|
TOTAL
MEDICAL DEVICES AND DIAGNOSTICS
|
|||||||||
|
US
|
2,766
|
2,648
|
4.5%
|
4.5%
|
-
|
||||
|
Intl
|
3,077
|
3,061
|
0.5%
|
3.8%
|
(3.3%)
|
||||
|
WW
|
5,843
|
5,709
|
2.3%
|
4.1%
|
(1.8%)
|
||||
Note: See footnotes at end of schedule
| REPORTED SALES vs. PRIOR PERIOD | |||||||||
| $MM | |||||||||
|
NINE
MONTHS
|
|||||||||
|
%
Change
|
|||||||||
|
2009
|
2008
|
Reported
|
Operational
(1)
|
Currency
|
|||||
|
MEDICAL
DEVICES AND DIAGNOSTICS (2)
(3)
|
|||||||||
|
CORDIS
(6)
|
|||||||||
|
US
|
731
|
929
|
(21.3%)
|
(21.3%)
|
-
|
||||
|
Intl
|
1,251
|
1,375
|
(9.0%)
|
(3.9%)
|
(5.1%)
|
||||
|
WW
|
1,982
|
2,304
|
(14.0%)
|
(10.9%)
|
(3.1%)
|
||||
|
DEPUY
|
|||||||||
|
US
|
2,268
|
2,129
|
6.5%
|
6.5%
|
-
|
||||
|
Intl
|
1,631
|
1,717
|
(5.0%)
|
6.8%
|
(11.8%)
|
||||
|
WW
|
3,899
|
3,846
|
1.4%
|
6.7%
|
(5.3%)
|
||||
|
DIABETES
CARE
|
|||||||||
|
US
|
908
|
990
|
(8.3%)
|
(8.3%)
|
-
|
||||
|
Intl
|
877
|
966
|
(9.2%)
|
0.2%
|
(9.4%)
|
||||
|
WW
|
1,785
|
1,956
|
(8.7%)
|
(4.1%)
|
(4.6%)
|
||||
|
ETHICON
|
|||||||||
|
US
|
1,296
|
1,087
|
19.2%
|
19.2%
|
-
|
||||
|
Intl
|
1,717
|
1,835
|
(6.4%)
|
3.6%
|
(10.0%)
|
||||
|
WW
|
3,013
|
2,922
|
3.1%
|
9.3%
|
(6.2%)
|
||||
|
ETHICON
ENDO-SURGERY
|
|||||||||
|
US
|
1,442
|
1,386
|
4.0%
|
4.0%
|
-
|
||||
|
Intl
|
1,794
|
1,783
|
0.6%
|
10.6%
|
(10.0%)
|
||||
|
WW
|
3,236
|
3,169
|
2.1%
|
7.7%
|
(5.6%)
|
||||
|
ORTHO-CLINICAL
DIAGNOSTICS
|
|||||||||
|
US
|
846
|
749
|
13.0%
|
13.0%
|
-
|
||||
|
Intl
|
616
|
640
|
(3.8%)
|
4.8%
|
(8.6%)
|
||||
|
WW
|
1,462
|
1,389
|
5.3%
|
9.3%
|
(4.0%)
|
||||
|
VISION
CARE
|
|||||||||
|
US
|
703
|
689
|
2.0%
|
2.0%
|
-
|
||||
|
Intl
|
1,185
|
1,209
|
(2.0%)
|
0.3%
|
(2.3%)
|
||||
|
WW
|
1,888
|
1,898
|
(0.5%)
|
0.9%
|
(1.4%)
|
||||
|
TOTAL
MEDICAL DEVICES AND DIAGNOSTICS
|
|||||||||
|
US
|
8,194
|
7,959
|
3.0%
|
3.0%
|
-
|
||||
|
Intl
|
9,071
|
9,525
|
(4.8%)
|
3.7%
|
(8.5%)
|
||||
|
WW
|
17,265
|
17,484
|
(1.3%)
|
3.3%
|
(4.6%)
|
||||
|
(1)
Operational growth excludes the effect of currency
|
|||||||||
|
(2)
Select areas (unaudited)
|
|||||||||
|
(3)
Prior year amounts have been reclassified to conform with current
presentation
|
|||||||||
|
(4)
Reported as U.S. sales
|
|||||||||
|
(5)
Included in Other
|
|||||||||
|
(6)
Includes sales of Drug-Eluting Stents for Q3 2009 of $53, $158 and $211MM
Domestic, International
and Worldwide respectively
|
|||||||||
|
Includes sales of Drug-Eluting Stents for Q3 2008 of $97, $192 and $289MM
Domestic, International
and Worldwide respectively
|
|||||||||
|
Includes sales of Drug-Eluting Stents for September YTD 2009 of $189, $507
and $696MM Domestic,
International and Worldwide respectively
|
|||||||||
|
Includes sales of Drug-Eluting Stents for September YTD 2008 of $433, $650
and $1,083MM Domestic,
International and Worldwide
respectively
|
|||||||||